A phase 1 study of eribulin mesylate (E7389), a novel microtubule-targeting chemotherapeutic agent, in children with refractory or recurrent solid tumors: A Children's Oncology Group Phase 1 Consortium study (ADVL1314)

Identification of microRNA biomarkers for response of advanced soft tissue sarcomas to eribulin: Translational results of the EORTC 62052 trial

(2017) Erik A.C. Wiemer et al.   EUROPEAN JOURNAL OF CANCER

Eribulin versus dacarbazine in previously treated patients with advanced liposarcoma or leiomyosarcoma: a randomised, open-label, multicentre, phase 3 trial

(2016) Patrick Schöffski et al.   LANCET

Eribulin in the management of inoperable soft-tissue sarcoma: patient selection and survival

(2016) Sujana Movva et al.   OncoTargets and Therapy

Pharmacodynamics (PD) and pharmacokinetics (PK) of E7389 (eribulin, halichondrin B analog) during a phase I trial in patients with advanced solid tumors: a California Cancer Consortium trial

(2015) Robert J. Morgan et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Eribulin mesilate suppresses experimental metastasis of breast cancer cells by reversing phenotype from epithelial–mesenchymal transition (EMT) to mesenchymal–epithelial transition (MET) states

(2014) T Yoshida et al.   BRITISH JOURNAL OF CANCER

Eribulin mesylate reduces tumor microenvironment abnormality by vascular remodeling in preclinical human breast cancer models

(2014) Yasuhiro Funahashi et al.   CANCER SCIENCE

Measuring Vincristine-Induced Peripheral Neuropathy in Children With Acute Lymphoblastic Leukemia

(2013) Ellen M. Lavoie Smith et al.   CANCER NURSING

Initial testing (stage 1) of eribulin, a novel tubulin binding agent, by the pediatric preclinical testing program

(2013) E. Anders Kolb et al.   PEDIATRIC BLOOD & CANCER

Antimitotic Inhibitors

(2012) Susana M. Campos et al.   HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA

A phase I, open-label, single-arm study for QT assessment of eribulin mesylate in patients with advanced solid tumors

(2012) Thierry Lesimple et al.   INVESTIGATIONAL NEW DRUGS

Eribulin mesylate in patients with refractory cancers: a Phase I study

(2011) Toru Mukohara et al.   INVESTIGATIONAL NEW DRUGS

Eribulin monotherapy versus treatment of physician's choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomised study

(2011) Javier Cortes et al.   LANCET

Activity of eribulin mesylate in patients with soft-tissue sarcoma: a phase 2 study in four independent histological subtypes

(2011) Patrick Schöffski et al.   LANCET ONCOLOGY

Phase II Trial of Ixabepilone Administered Daily for Five Days in Children and Young Adults with Refractory Solid Tumors: A Report from the Children's Oncology Group

(2010) S. Jacobs et al.   CLINICAL CANCER RESEARCH

Interactions between the chemotherapeutic agent eribulin mesylate (E7389) and P-glycoprotein in CF-1 abcb1a-deficient mice and Caco-2 cells

(2010) Jan-Shiang Taur et al.   XENOBIOTICA

Phase I Study of Eribulin Mesylate Administered Once Every 21 Days in Patients with Advanced Solid Tumors

(2009) A. R. Tan et al.   CLINICAL CANCER RESEARCH

Phase II Study of Eribulin Mesylate, a Halichondrin B Analog, in Patients With Metastatic Breast Cancer Previously Treated With an Anthracycline and a Taxane

(2009) Linda T. Vahdat et al.   JOURNAL OF CLINICAL ONCOLOGY

Microtubule inhibitors: Differentiating tubulin-inhibiting agents based on mechanisms of action, clinical activity, and resistance

(2009) E. A. Perez   MOLECULAR CANCER THERAPEUTICS

Vincristine: Can its therapeutic index be enhanced?

(2009) Andrew Moore et al.   PEDIATRIC BLOOD & CANCER

New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)

(2008) E.A. Eisenhauer et al.   EUROPEAN JOURNAL OF CANCER

Shortening the Timeline of Pediatric Phase I Trials: The Rolling Six Design

(2008) Jeffrey M. Skolnik et al.   JOURNAL OF CLINICAL ONCOLOGY

A Phase 1 and pharmacokinetic clinical trial of paclitaxel for the treatment of refractory leukemia in children: A Children's Oncology Group study

(2007) Terzah M. Horton et al.   PEDIATRIC BLOOD & CANCER